Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects

British Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 15-23

  Sun, De Qing ^a   Wang, Hai Sheng ^a   Ni, Mei Yuan ^b   Wang, Ben Jie ^b   Guo, Rui Chen ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Healthy Chinese subject; Pharmacokinetics; Safety; Tolerance

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CREATINE KINASE; LACTATE DEHYDROGENASE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PHOSPHONIC ACIDS;

EID: 33845461435     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02728.x     Document Type: Article

References (15)

1. Buti M, Esteban R. Adefovir dipivoxil. Drugs Today (Barc) 2003; 39: 127-35.
2. Shaw JP, Louie MS, Krishnamurthy VV, Arimilli MN, Jones RJ, Bidgood AM, Lee WA, Cundy KC. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab Dispos 1997; 25: 362-6.
3. Ray AS, Vela JE, Olson L, Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem Pharmacol 2004; 68: 1825-31.
4. Seigneres B, Aguesse-Germon S, Pichoud C, Vuillermoz I, Jamard C, Trepo C, Zoulim F. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol 2001; 34: 114-22.
5. FDA. Advisory Committee Briefing Document. Adefovir Dipivoxil for the Treatment of Chronic Hepatitis B. Available at http://www.fda.gov/ohrms/dockets/ ac/02/briefing/3885B1-01_Gilead.pdf (last accessed: 17 October 2005).
6. Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, Jaffe HS. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1995; 39: 2401-5.
7. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36: 127-43.
8. Ji-dong JIA, Zhuang H. The overview of the seminar on chronic hepatitis B. Chin J Hepatol 2004; 12: 698-9.
9. Dusheiko G. Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. J Hepatol 2003; 39 (Suppl. 1): S116-23.
10. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
11. Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44: 1041-6.
12. Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, Lietman PS. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)- phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997; 176: 406-13.
13. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176: 1517-23.
14. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V, Heubi JE. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 2003; 133: 1027-35.
15. Gilead Sciences. A Phase I/II Study of the Safety, Tolerance, Pharmacokinetics and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl) Phosphonomethoxy) ethyl]Adenine (bis-POM PMEA) and Placebo in HIV-Infected Patients. GS-94-402. : Gilead Sciences Protocol Inc., Foster City, CA. 1994.